Cellectis Toekomstige groei

Future criteriumcontroles 2/6

Er wordt voorspeld dat Cellectis de winst en omzet met respectievelijk 25.9% en 29.2% per jaar zal laten groeien.

Belangrijke informatie

25.9%

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	29.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	07 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 30

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

May 30

FDA clears Cellectis' investigational new drug application for lymphoma treatment

Aug 01

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Jul 13

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Jun 22

Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform

Jun 15

Cellectis withdraws follow-on offering

Dec 16

Cellectis initiates equity raise of $100M

Dec 14

FDA lifts clinical hold on Cellectis' early-stage UCARTCS1 study in multiple myeloma

Nov 18

Cellectis EPS misses by $0.10, misses on revenue

Nov 05

Winst- en omzetgroeiprognoses

NasdaqGM:CLLS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	116	-47	-77	N/A	3
12/31/2025	67	-48	-96	N/A	6
12/31/2024	44	-57	8	N/A	5
9/30/2024	36	-84	60	63	N/A
6/30/2024	20	-79	51	51	N/A
3/31/2024	12	-78	-21	-20	N/A
12/31/2023	9	-109	-26	-25	N/A
9/30/2023	25	-92	-67	-66	N/A
6/30/2023	25	-97	-78	-75	N/A
3/31/2023	25	-91	-81	-79	N/A
12/31/2022	26	-91	-90	-87	N/A
9/30/2022	-5	-63	-109	-107	N/A
6/30/2022	4	-78	-118	-112	N/A
3/31/2022	14	-99	-111	-100	N/A
12/31/2021	39	-86	-123	-105	N/A
9/30/2021	68	-129	-154	-117	N/A
6/30/2021	67	-121	-151	-113	N/A
3/31/2021	59	-113	-169	-123	N/A
12/31/2020	60	-37	-125	-80	N/A
9/30/2020	73	-79	-80	-49	N/A
6/30/2020	73	-66	-76	-46	N/A
3/31/2020	71	-67	-64	-45	N/A
12/31/2019	23	-102	-82	-69	N/A
9/30/2019	20	-88	-100	-87	N/A
6/30/2019	11	-95	-88	-79	N/A
3/31/2019	17	-69	-77	-71	N/A
12/31/2018	21	-79	-73	-68	N/A
9/30/2018	25	-83	-60	-57	N/A
6/30/2018	31	-86	N/A	-58	N/A
3/31/2018	31	-105	N/A	-56	N/A
12/31/2017	34	-99	N/A	-52	N/A
9/30/2017	40	-86	N/A	-41	N/A
6/30/2017	45	-74	N/A	N/A	N/A
3/31/2017	57	-56	N/A	-28	N/A
12/31/2016	56	-67	N/A	-33	N/A
9/30/2016	76	-45	N/A	-6	N/A
6/30/2016	74	-45	N/A	N/A	N/A
3/31/2016	65	-64	N/A	-17	N/A
12/31/2015	63	-23	N/A	4	N/A
9/30/2015	39	-28	N/A	2	N/A
6/30/2015	37	-10	N/A	34	N/A
3/31/2015	33	12	N/A	47	N/A
12/31/2014	32	3	N/A	51	N/A
9/30/2014	28	-8	N/A	18	N/A
6/30/2014	24	-21	N/A	-18	N/A
3/31/2014	21	-29	N/A	-22	N/A
12/31/2013	18	-36	N/A	-26	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLLS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLLS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLLS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLLS ( 29.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CLLS ( 29.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CLLS naar verwachting over 3 jaar hoog zal zijn

Cellectis Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

Cellectis Announces Chief Financial Officer Changes

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

FDA clears Cellectis' investigational new drug application for lymphoma treatment

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

Cellectis withdraws follow-on offering

Cellectis initiates equity raise of $100M

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

FDA lifts clinical hold on Cellectis' early-stage UCARTCS1 study in multiple myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Cellectis S.A. Appoints Jean-Pierre Garnier, Ph.D as Non-Executive Chairman of the Board of Directors

Cellectis EPS misses by $0.10, misses on revenue

Cellectis S.A. to Report Q2, 2020 Results on Aug 05, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven